Skip NavigationSkip to Content
Return Return to Search Results

MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus

  1. Author:
    DeBarros, Kenya [ORCID]
    Khan, Mahfuz [ORCID]
    Coleman, Morgan
    Bond, Vincent C [ORCID]
    Floyd, Virginia
    Gbodossou, Erick
    Diop, Amad
    Krumpe,Lauren
    O'Keefe,Barry [ORCID]
    Powell, Michael D [ORCID]

  2. Author Address

    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., Department of Community Health and Preventive Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., PROMETRA International, Dakar-Etoile BP 6134, Senegal., Malango Traditional Healers Association, Fatick BP 1763, Senegal., Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA., Natural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, USA.,
    1. Year: 2024
    2. Date: Sep 07
    3. Epub Date: 2024 09 07
  2. Journal: Viruses
    1. 16
    2. 9
  4. Type of Article: Article
  5. Article Number: 1433
  1. Abstract:

    MoMo30 is an antiviral protein isolated from aqueous extracts of Momordica balsamina L. (Senegalese bitter melon). Previously, we demonstrated MoMo30's antiviral activity against HIV-1. Here, we explore whether MoMo30 has antiviral activity against the COVID-19 virus, SARS-CoV-2. MLV particles pseudotyped with the SARS-CoV-2 Spike glycoprotein and a Luciferase reporter gene (SARS2-PsV) were developed from a three-way co-transfection of HEK293-T17 cells. MoMo30's inhibition of SARS2-PsV infection was measured using a luciferase assay and its cytotoxicity using an XTT assay. Additionally, MoMo30's interactions with the variants and domains of Spike were determined by ELISA. We show that MoMo30 inhibits SARS2-PsV infection. We also report evidence of the direct interaction of MoMo30 and SARS-CoV-2 Spike from WH-1, Alpha, Delta, and Omicron variants. Furthermore, MoMo30 interacts with both the S1 and S2 domains of Spike but not the receptor binding domain (RBD), suggesting that MoMo30 inhibits SARS-CoV-2 infection by inhibiting fusion of the virus and the host cell via interactions with Spike.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/v16091433
  3. PMID: 39339909
  4. PMCID: PMC11437407
  5. PII : v16091433

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel